Literature DB >> 2354119

Cyclosporin A treatment of systemic sclerosis.

H Zachariae1, L Halkier-Sørensen, L Heickendorff, E Zachariae, H E Hansen.   

Abstract

Ten patients with severe progressive systemic sclerosis were treated with cyclosporin A at dosages of 1.5-7.5 mg/kg per day:two patients showed a marked improvement with softening of the involved skin; in one patient there was healing of persistent digital ulcers; one patient showed initial improvement followed by a marked exacerbation; one patient was slightly improved; two patients were unchanged. The clinical results correlated well with levels of serum aminoterminal propeptide of type III procollagen. In the eight patients completing treatment, side-effects such as slight tremor and a transient increase in the serum creatinine and blood pressure were either absent or reverted to normal when the dosage was decreased, except one case who had to be treated with anti-hypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354119     DOI: 10.1111/j.1365-2133.1990.tb07290.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

4.  Progressive systemic sclerosis with CNS vasculitis and cyclosporin A therapy.

Authors:  K Ishida; T Kamata; H Tsukagoshi; Y Tanizaki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

Review 5.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 6.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

7.  Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal.

Authors:  P Casoli; C Carretti; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 9.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.